Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of BMS-986166 in Healthy Subjects
NCT03038711Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of udifitimod in ulcerative colitis (UC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of All Adverse Events (AEs) at 77 days, Incidence of Serious Adverse Events (SAEs) at 77 days and 9 more. Started Feb 2017; status: completed.
02
Drugs
udifitimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03038711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038711.